SHR 2017
Alternative Names: SHR-2017Latest Information Update: 21 Jun 2024
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Class Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Osteoporosis; Solid tumours
Most Recent Events
- 20 May 2024 Phase-I clinical trials in Solid tumours in China (Parenteral) (NCT06380881)
- 24 Apr 2024 Suzhou Suncadia Biopharmaceuticals plans phase-Ib trial for Bone Metastases (Injection) in China in April 2024 (NCT06380881)
- 10 Jul 2023 Suzhou Suncadia Biopharmaceuticals plans a phase I trial(In Adults, In the Elderly) for Osteoporosis in China (NCT05930704)